

AD _____

Award Number: DAMD17-03-1-0671

TITLE: The Role of Protein Elongation Factor EEF1A2 in Breast Cancer

PRINCIPAL INVESTIGATOR: Jonathan M. Lee, Ph.D.

CONTRACTING ORGANIZATION: Hamilton Regional Cancer Centre
Hamilton, Ontario, Canada L8V 5C2

REPORT DATE: September 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050415 151

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

| | | | | |
|---|---|--|---|--|
| 1. AGENCY USE ONLY (Leave blank) | | 2. REPORT DATE September 2004 | 3. REPORT TYPE AND DATES COVERED Annual (15 Aug 2003 - 14 Aug 2004) | |
| 4. TITLE AND SUBTITLE The Role of Protein Elongation Factor EEF1A2 in Breast Cancer | | | 5. FUNDING NUMBERS DAMD17-03-1-0671 | |
| 6. AUTHOR(S) Jonathan M. Lee, Ph.D. | | | | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Hamilton Regional Cancer Centre Hamilton, Ontario, Canada L8V 5C2 E-Mail: jlee@uottawa.ca | | | 8. PERFORMING ORGANIZATION REPORT NUMBER | |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 | | | 10. SPONSORING / MONITORING AGENCY REPORT NUMBER | |
| 11. SUPPLEMENTARY NOTES | | | | |
| 12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited | | | 12b. DISTRIBUTION CODE | |
| 13. ABSTRACT (Maximum 200 Words) <p>The overall goal of the project is to explore the idea that protein elongation factor EEF1A2 has an important causal role in breast tumour development and that EEF1A2 gene amplification and protein overexpression can be used as a breast cancer prognostic factor. In addition, we proposed to test the idea that EEF1A2 expression modulates sensitivity to cisplatin and taxol and that EEF1A2-inactivation could be used as a treatment for breast cancer.</p> <p>In the one-year period since funding has been received, we have made progress in the following areas: 1. We have determined that approximately 25% of primary human breast tumours highly express EEF1A2; 2. We identified two human breast cancer cell lines that highly express EEF1A2 (MCF7 and BT474) and two that do not (MCF10A and BT549); 3. We created MCF10A and BT549 variants that highly express EEF1A2 and determined that EEF1A2 enhances the in vitro growth of these variants compared to control; 4. We have created an EEF1A2 transgenic mouse; 5. We have created antisense oligonucleotides (AS) and siRNA that specifically inactivate EEF1A2; 6. We determined that the AS and siRNA inhibit the growth of MCF7 in vitro.</p> | | | | |
| 14. SUBJECT TERMS oncogene, gene amplification, tissue microarray, FISH, primary breast Tumours, cell lines, transformation, protein elongation, transgenic | | | 15. NUMBER OF PAGES 10 | |
| | | | 16. PRICE CODE | |
| 17. SECURITY CLASSIFICATION OF REPORT Unclassified | 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified | 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified | 20. LIMITATION OF ABSTRACT Unlimited | |

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

| | |
|-----------------------------------|---|
| Cover..... | 1 |
| SF 298..... | 2 |
| Table of Contents..... | 3 |
| Introduction..... | 4 |
| Body..... | 4 |
| Key Research Accomplishments..... | 5 |
| Reportable Outcomes..... | 5 |
| Conclusions..... | 5 |
| References..... | 5 |
| Appendices..... | 6 |

Introduction

The development of cancer is associated with DNA amplifications that are believed to have a causative role in oncogenesis. We have previously found that amplifications of the *EEF1A2* gene and its overexpression is associated with approximately 1/3 of primary ovarian cancers (Anand, Murthy et al. 2002). We found that *EEF1A2* has the growth-enhancing and transforming properties of an oncogene (Anand, Murthy et al. 2002), consistent with it having a causal role in neoplasia (Thornton, Anand et al. 2003). The overall goal of the project is to explore the idea that protein elongation factor *EEF1A2* has an important causal role in breast tumour development and that *EEF1A2* gene amplification and protein overexpression can be used as a breast cancer prognostic factor. In addition, we proposed to test the idea *EEF1A2*-inactivation could be used as a treatment for breast cancer.

Body

Progress has been made in the following areas:

Task 1. Determine whether *EEF1A2* enhances cell growth and tumorigenicity. To this end we have analyzed *EEF1A2* expression in a panel of breast cancer cell lines (fig 1) and identified breast cell lines that highly express *EEF1A2* (MCF7 and BT474) and those that do not do so (MCF10A and BT549). We have made a variants of MCF10A and BT549 that ectopically expresses *EEF1A2* (fig 2-3). We have found that *EEF1A2* expression in MCF10A and BT549 increases their in vitro growth rate (fig 4), consistent with the idea that *EEF1A2* is a breast cancer oncogene. We are now testing the effect that *EEF1A2* expression has on growth in soft agar and tumorigenicity in nude mice.

Task 2. Determine whether mammary-specific *EEF1A2* expression enhances mammary tumorigenesis. To this end, we have derived an expression vector where the MMTV promoter controls *EEF1A2* expression. This plasmid was used for three rounds of microinjection. Pups were weaned June 14, 2004 and we have identified 9 founder lines. We have 90 pups from an F1 cross utilizing 6 founder animals. We are currently testing each line for mammary-specific expression.

Task 3 .Determine the prognostic significance of *EEF1A2* in breast cancer. There are two overall aims of this section a) Correlate *EEF1A2* gene amplification with clinical and histological parameters, b) Create and *EEF1A2* antibody and correlate *EEF1A2* protein expression with clinical and histological parameters. As shown in Fig 5, increased *EEF1A2* copy number correlates with reduced significantly reduced 10-year survival data in a n=142 cohort of breast cancer patients. We are now testing a larger (n=600) cohort. The generation of an *EEF1A2* antibody for Task 3b has been more difficult. Our first attempt at immunization using the SHTTLLEAVDCIL peptide led to the generation of polyclonal rabbit sera that was equally reactive against *EEF1A2* and the related *eEF1A1* protein. This serum could therefore not be used for the necessary study. We have immunized rabbits with a new peptide and we are now testing this antibody.

Task 4. Determine whether *EEF1A2* inactivation can be used as a treatment for breast cancer. To this end, we have identified an *EEF1A2* phospho-orthoioated antisense that can reduce *EEF1A2* expression in the MCF7 breast cancer cell line (fig 6). This antisense appears to inhibit MCF7 growth (fig 7). We have also designed *EEF1A2*-inactivating antisense (fig 8) and these inhibit MCF7 growth in vitro (fig 9). We are currently testing these agents for in vivo efficacy.

Key Research Accomplishments

We have determined that EEF1A2 gene amplification correlates with poor 10-year survival (n=142).

We have determined that approximately 25% of primary human breast tumours highly express EEF1A2.

We identified two human breast cancer cell lines that highly express EEF1A2 (MCF7 and BT474) and two that do not (MCF10A and BT549).

We created MCF10A and BT549 variants that highly express EEF1A2 and determined that EEF1A2 enhances the *in vitro* growth of these variants compared to control.

We have created an EEF1A2 transgenic mouse.

We have created antisense oligonucleotides (AS) and siRNA that specifically inactivate EEF1A2.

We determined that the AS and siRNA inhibit the growth of MCF7 *in vitro*.

Reportable Outcomes

We created MCF10A and BT549 variants that highly express EEF1A2 and determined that EEF1A2 enhances the *in vitro* growth of these variants compared to control.

We have made an EEF1A2/MMTV promoter plasmid

We have created an EEF1A2 transgenic mouse.

We have created antisense oligonucleotides (AS) and siRNA that specifically inactivate EEF1A2.

Conclusions

We have determined that EEF1A2 expression enhances the *in vitro* growth of breast cancer cell lines and that EEF1A2 gene amplification correlates with poor clinical outcome in women with breast cancer. These observations are consistent with the idea that EEF1A2 is a novel and important breast cancer oncogene. We have made an EEF1A2 transgenic mouse that may be an important animal model for breast cancer. Furthermore, we have identified EEF1A2-inactivating agents that may be used as anti-breast cancer treatments.

References

Anand, N., S. Murthy, et al. (2002). "Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer." Nat Genet **31**(3): 301-5.

Thornton, S., N. Anand, et al. (2003). "Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis." J Mol Med **81**(9): 536-48.

Appendix




Figure 1. eEF1A2 mRNA expression in breast cancer cell lines. The breast lines BT 474 and MCF7 express detectable eEF1A2 mRNA while BT 59, MBA 231 and MCF10AT do not.




Figure 2. Creation of BT-549 cells ectopically expressing eEF1A2. The eEF1A2 non-expressing BT549 cell line was stably transfected with eEF1A2 and expression detected by Western blotting.




Figure 3. Creation of MCF-10AT cells ectopically expressing eEF1A2. The eEF1A2 non-expressing MCF10AT cell line was stably transfected with eEF1A2 and expression detected by Western blotting.




Figure 4. eEF1A2 expression in BT549 and MCF10AT enhances in vitro growth rate. The growth rate of eEF1A2-expressing variants of BT549 (left panel) and MCF10AT (right panel) grow faster than controls. Growth was measured by counting viable cells (Trypan Blue) at the indicated times following initial plating. Data points are the mean and standard deviation of triplicate measurements.




Figure 5. *EEF1A2* increase in copy number is associated with reduced survival in breast cancer. Women with >4 copies of *EEF1A2* in their tumours (purple line) have a reduced probability of 10-year survival compared to those with normal *EEF1A2* copy number (green line)




Figure 6. Antisense inhibition of *EEF1A2*. A) *EEF1A2* antisense but not scrambled control reduced *EEF1A2* levels in MCF7 cells.




Figure 7. Antisense inhibition of EEF1A2 inhibits MCF7 growth. Antisense inhibits growth of MCF7 cells as measured by trypan blue exclusion. Data points are the mean and standard deviation of triplicate measurements. Antisense (Antisense 1 from fig 6) was used in a single dose of 200nM.




Figure 8. siRNA that inhibit EEF1A2 production. Three siRNA (Ambion) were tested for their ability to prevent EEF1A2 production. SiRNA #7 and #8 are effective.

EFFECT OF eEF1A2-DIRECTED siRNA ON MCF 7 CELL GROWTH




Figure 9. EEF1A2 siRNA inhibits MCF7 growth. siRNA (#7 from fig 8) inhibits in vitro growth of MCF7 cells as measured by trypan blue exclusion. Data points are the mean and standard deviation of triplicate measurements.